Transgene (DB:TGNA) - Stock Price, News & Analysis

TGNA Stock Overview

A biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. More details

TGNA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 34.8% per year for the next 3 years

Negative shareholders equity

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 2 more risks

Transgene SA Competitors

Heidelberg Pharma

XTRA:HPHA

€101.1m

Medigene

XTRA:MDG1

€23.7m

2invest

XTRA:2INV

€62.7m

Formycon

XTRA:FYB

€821.0m

Price History & Performance

Summary of all time highs, changes and price drops for Transgene
Historical stock prices
Current Share Price	€0.77
52 Week High	€1.45
52 Week Low	€0.75
Beta	0.80
11 Month Change	-20.93%
3 Month Change	-24.66%
1 Year Change	-46.36%
33 Year Change	-71.85%
5 Year Change	-59.20%
Change since IPO	-98.21%

Recent updates

Shareholder Returns

	TGNA	DE Biotechs	DE Market
7D	-8.8%	0.8%	-0.4%
1Y	-46.4%	-16.7%	7.1%

Return vs Industry: TGNA underperformed the German Biotechs industry which returned -16.7% over the past year.

Return vs Market: TGNA underperformed the German Market which returned 7.1% over the past year.

Price Volatility

Is TGNA's price volatile compared to industry and market?
TGNA volatility
TGNA Average Weekly Movement	9.0%
Biotechs Industry Average Movement	6.3%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: TGNA's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: TGNA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1979	146	Alessandro Riva	www.transgene.fr

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.

Transgene SA Fundamentals Summary

How do Transgene's earnings and revenue compare to its market cap?
TGNA fundamental statistics
Market cap	€103.22m
Earnings (TTM)	-€22.91m
Revenue (TTM)	€6.49m

15.9x

P/S Ratio

-4.5x

P/E Ratio

Is TGNA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TGNA income statement (TTM)
Revenue	€6.49m
Cost of Revenue	€29.44m
Gross Profit	-€22.95m
Other Expenses	-€37.00k
Earnings	-€22.91m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.17
Gross Margin	-353.37%
Net Profit Margin	-352.80%
Debt/Equity Ratio	-5,956.7%

How did TGNA perform over the long term?

See historical performance and comparison

TGNA Stock Overview

Risk Analysis

Transgene SA Competitors

XTRA:HPHA

€101.1m

XTRA:MDG1

€23.7m

XTRA:2INV

€62.7m

XTRA:FYB

€821.0m

Price History & Performance

Recent News & Updates

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

First half 2024 earnings released: €0.16 loss per share (vs €0.16 loss in 1H 2023)

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

New minor risk - Shareholder dilution

Less than half of directors are independent

New major risk - Financial position

Recent updates

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

First half 2024 earnings released: €0.16 loss per share (vs €0.16 loss in 1H 2023)

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

New minor risk - Shareholder dilution

Less than half of directors are independent

New major risk - Financial position

Full year 2023 earnings released: €0.22 loss per share (vs €0.33 loss in FY 2022)

Transgene SA Announces Chief Financial Officer Changes

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

First half 2023 earnings released: €0.16 loss per share (vs €0.15 loss in 1H 2022)

First half 2023 earnings released

New major risk - Financial position

New minor risk - Share price stability

BioInvent Ready for Combination Studies with BT-001

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Transgene SA Appoints Carol Stuckley as Independent Director

Full year 2022 earnings released: €0.33 loss per share (vs €0.21 loss in FY 2021)

Transgene Receives Approval to Start a Phase I Trial of TG6050

Transgene SA to Report First Half, 2023 Results on Sep 20, 2023

No longer forecast to breakeven

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab Vs Avelumab in HPV-Positive Anogenital Cancers

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

First half 2022 earnings released

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Transgene SA Presented Additional Phase I Data with TG4050 at ASCO 2022

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® Platform) At Asco 2022

Transgene SA Approves Board and Committee Changes

No longer forecast to breakeven

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

No longer forecast to breakeven

Transgene to Present New Positive Preliminary Phase I Data on TG4050

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies of TG4050, A Novel Individualized Neoantigen Cancer Vaccine

First half 2021 earnings released

Transgene Announces Update on Phase I Clinical Trial of TG4050

Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg4001 + Avelumab Vs Avelumab Alone in Patients with HPV16-Positive Anogenital Cancers

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors

Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001

Transgene SA Develops Individualized Immunotherapy Based on Multiple Advanced Genetic Engineering Technologies

Full year 2020 earnings released: €0.21 loss per share (vs €0.23 loss in FY 2019)

Revenue misses expectations

New 90-day high: €2.84

Transgene and BioInvent International AB Enroll First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

New 90-day high: €2.69

New 90-day high: €2.60

Transgene SA Announces the First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgene’s Innovative Individualized Immunotherapy

Transgene Sa and Bioinvent Receive Approval from Ansm to Proceed with Phase I/Iia Trial of Anti-Ctla4-Armed Oncolytic Virus Bt-001 in Solid Tumors

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

New 90-day high: €1.74

Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors

Transgene SA, Annual General Meeting, May 26, 2021

Transgene Announces Management Changes

First half 2020 earnings released: €0.03 loss per share

New 90-day high: €1.57

Transgene SA Announces the Presentation of the Detailed Results from the Phase 1b/2 Trial Combining TG4001, a HPV16-Targeted Therapeutic Vaccine, with Avelumab (BAVENCIO®)

Transgene Announces Detailed Results from the Phase 1B/2 Trial Combining TG4001

Transgene Announces Detailed Results of the Data from the Phase 1b/2 Trial Combining TG4001

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers